Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The 71-year-old grandfather with metastatic melanoma had flown in from ...

Personalized cell therapies have emerged as powerful treatments for cancers and other diseases but producing them remains a complex engineering challenge. Unlike conventional drugs, each cell therapy ...

From data lakes to streamlined production, Kriya, Opus, and Epicrispr discuss how technology is improving their operations.

Cell and gene therapies (CGTs) are built on living systems. From early research through commercial distribution, the integrity of those systems depends on the ability to preserve cells without ...

Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. "This is a quantum leap in ...

The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to ...

CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The ...

New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical production to support the development of cell therapies for cancer, ...

Cell therapy manufacturing has long been constrained by manual bottlenecks - steps that are labor-intensive, variable, and difficult to scale. Robotic automation is increasingly becoming key to ...

Cellares has raised a $257 million Series D financing, bringing its total funding to $612 million. The latest comes as the cell therapy manufacturing company accelerates plans to industrialize ...

A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...

BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today ...